Navigation Links
AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Date:9/1/2009

QUEBEC CITY, Sept. 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, M.D., will present a corporate overview at the upcoming Rodman Renshaw Annual Global Investment Conference on Wednesday, September 9, 2009 at 12:30 p.m. (eastern time) in the Spellman Salon (5th floor) of the New York Palace Hotel in New York City.

A live webcast of the presentation will be available on AEterna Zentaris' website at www.aezsinc.com in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
4. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
5. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
6. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
7. AEterna Zentaris Receives US$10 Million from Institutional Investors
8. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
9. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
11. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... (PRWEB) , ... November 12, 2019 , ... ... DNA services, welcomed their new Director of Forensic Genealogy, Melinde Lutz Byrne, to ... Service (FGS) to ultimately provide investigative leads to law enforcement through proven ...
(Date:11/9/2019)... , ... November 08, 2019 ... ... artificial intelligence (AI)-powered technology for use in pathology research, today announced the ... biopsy samples from patients enrolled in the phase 3 selonsertib studies (STELLAR). ...
(Date:11/6/2019)... ... November 06, 2019 , ... LeadingBiotech ,?an ... today announces its East/West CEO conference to be held January 11-12, ... , Kicking off the week of the J.P. Morgan Healthcare Conference and other ...
(Date:11/5/2019)... ... November 05, 2019 , ... Focal Healthcare , ... for its Fusion Bx 2.0 prostate fusion biopsy solution. By combining information from ... 2.0 will give urologists across Europe the ability to perform targeted transrectal and ...
Breaking Biology Technology:
(Date:11/14/2019)... ... 13, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... approved clinical trial for stem cell treatment of knee osteoarthritis . The first treatment ... subsidiary of VetStem Biopharma. , In July of 2019, PSC received FDA approval ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... the design and manufacturer of technical ergonomic seating solutions, announced this week ... with Healthier Hospital Initiative guidelines. Established by Practice Greenhealth, a health care ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... proposals from nonprofit U.S. universities and research institutions for its Instrumentation Grant ... of up to $1.2 million per site for the acquisition of instrumentation, development ...
Breaking Biology News(10 mins):